Cell and Gene Therapy Innovator Castle Creek Biosciences Appoints Matthew Gantz as President and Chief Executive Officer
- Life sciences executive brings more than 25 years of experience to cell and gene therapy company progressing through pivotal Phase 3 clinical trial -
News provided by
Share this article
Share this article
EXTON, Pa., April 20, 2021 /PRNewswire/ Castle Creek Biosciences, Inc. (the Company ), a privately held, clinical-stage cell and gene therapy company leveraging its proprietary fibroblast technology platform to develop and commercialize disease-modifying therapies for patients suffering from orphan conditions for which there is a lack of available treatment options, today announced that Matthew Gantz has been appointed President and Chief Executive Officer. He will also serve as a member of the Company s Board of Directors. Mr. Gantz succeeds John Maslowski, who will continue to serve the company as Chief Operating Officer.
Rhythm Pharmaceuticals, Inc.: Rhythm Pharmaceuticals to Present at 20th Annual Needham Virtual Healthcare Conference
BOSTON, April 07, 2021 (GLOBE NEWSWIRE) Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in a fireside chat at the 20
th Annual Needham & Co. Virtual Healthcare Conference on Wednesday, April 14, 2021 at 11:45 a.m. ET.
A live audio webcast of the presentation will be available under Events & Presentations in the Investor Relations section of the Company s website at www.rhythmtx.com. A replay of the webcast will be available on the Rhythm website for 30 days following each presentation.
LogicBio Therapeutics Reports Full Year 2020 Financial Results and Provides Business Update
- First patient for Phase 1/2 SUNRISE trial expected to be enrolled in early 2021
-Translational preclinical data for sAAVy platform shows substantial improvements over liver tropic capsids used in gene therapy programs to date
-New Chief Scientific and Chief Financial Officers recently added to Executive Team
News provided by
Share this article
Share this article
LEXINGTON, Mass., March 15, 2021 /PRNewswire/ LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a clinical- stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today reported financial results for the year ended December 31, 2020 and provided a business update.
LogicBio Therapeutics to Present at Upcoming Investor Conferences
News provided by
Share this article
Share this article
LEXINGTON, Mass., Feb. 26, 2021 /PRNewswire/ LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced that chief executive officer Frederic Chereau will be presenting an overview of the company at upcoming investor conferences.
Mr. Chereau will present at the Barclays Global Healthcare Conference on Thursday, March 11, 2021 at 4:10 p.m. ET. A link to the Barclays presentation will be available under the Events and Presentations section of LogicBio s website, found here: https://investor.logicbio.com/events-and-presentations/events.
Chiesi Global Rare Diseases Recognizes Rare Disease Day Highlighting Importance of Staying Connected for Information and Support
Company sponsors #wewearstripes social media campaign calling on participants to share photos to express support for people affected by rare diseases
Company to light up offices around the world including Italy, the United States, and Canada
News provided by
Share this article
Share this article
BOSTON, Feb. 26, 2021 /PRNewswire/ Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), is recognizing Rare Disease Day (RDD) 2021 and joins with the global community to support efforts to help patients and families affected by rare diseases to stay connected and access the support and information they need.